目的:通过以血栓形成为首发表现的恶性肿瘤患者分析,探讨血栓与恶性肿瘤之间的关系.方法:从以下几个方面发现以血栓形成为首发表现的恶性肿瘤患者的临床特征:患者的临床表现、栓塞部位、原发肿瘤的部位及分期、统计发现血栓至确诊恶性肿瘤的时间、肿瘤治疗效果、随访生存情况,为以血栓形成为首发表现的恶性肿瘤患者血栓与肿瘤之间的关系提供依据.结果:以血栓形成为首发表现的恶性肿瘤患者中, IV期患者占60%,40%患者失去抗肿瘤治疗机会,抗肿瘤治疗的近期有效率为41. 7%,死亡率为55%.结论:有血栓形成的患者应警惕恶性肿瘤的发生,注意筛查,以利肿瘤的早期发现、早期治疗.%Objective:To discuss the relationship between thrombus and malignant tumor through analyzing the pa-tients followed by malignant tumor with thrombosis as the first manifestation. Methods:To provide evidences for the relationship between thrombus and malignant tumor through the clinical features found in patient followed by malig-nant tumor with thrombosis as the first manifestation from the following aspects:Clinical manifestation,embolism posi-tion,the site and stage of the primary tumor,time from thrombosis to the diagnosis of malignant tumor,the effect of anti-tumor treatment and the follow-up survival. Results:In the patients with malignant tumor with thrombosis as the first manifestation,the patients in stage IV accounted for 60%. 40% of patients losedthe opportunities of anti-tumor treatment,and the recent effective rate and mortality rate of anti-tumor treatment were 41. 7% and 55% respective-ly. Conclusion:Patients with thrombosis should be alert to the occurrence of malignant tumors,and pay attention to screening to facilitate the early detection and early treatment of tumors.
展开▼
机译:随机,安慰剂对照,FosapRepitant,Ondansetron,Dexamethasone(喜欢的)与Fond Plus Olanzapine(FONE-O)进行血液学恶性肿瘤患者的血液学恶性肿瘤患者呕吐,ondansetron,ondansetron(Fond-O)的试验。接受高均匀化疗和造血细胞移植的血液学恶性肿瘤患者 方案:FOND-O试验